Your browser doesn't support javascript.
loading
Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml.
Ornstein, David K; Rayford, Walter; Fusaro, Vincent A; Conrads, Thomas P; Ross, Sally J; Hitt, Ben A; Wiggins, Wesley W; Veenstra, Timothy D; Liotta, Lance A; Petricoin, Emanuel F.
Affiliation
  • Ornstein DK; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA. dornestei@uci.edu
J Urol ; 172(4 Pt 1): 1302-5, 2004 Oct.
Article in En | MEDLINE | ID: mdl-15371828
Subject(s)
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Hyperplasia / Prostatic Neoplasms / Mass Spectrometry / Artificial Intelligence / Biomarkers, Tumor / Diagnosis, Computer-Assisted / Prostate-Specific Antigen / Proteomics Type of study: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies Limits: Humans / Male Language: En Journal: J Urol Year: 2004 Document type: Article Affiliation country: United States Country of publication: United States
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Hyperplasia / Prostatic Neoplasms / Mass Spectrometry / Artificial Intelligence / Biomarkers, Tumor / Diagnosis, Computer-Assisted / Prostate-Specific Antigen / Proteomics Type of study: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies Limits: Humans / Male Language: En Journal: J Urol Year: 2004 Document type: Article Affiliation country: United States Country of publication: United States